From Nasdaq: 2025-03-31 19:05:00

Orchestra BioMed Holdings, Inc. (OBIO) reported a quarterly loss of $0.43 per share, in line with expectations but higher than last year. The company missed revenue estimates by 67.85%. Shares have gained 10% this year. Investors are now looking at the company’s earnings outlook and estimate revisions for future performance.

Exelixis (EXEL), a drug developer in the same industry, is expected to post quarterly earnings of $0.41 per share, up 141.2% year-over-year. Revenue is expected to increase by 18.2% from the year-ago quarter. Both companies are being closely watched for their financial performance and industry outlook for potential investment opportunities.

For investors considering Orchestra BioMed Holdings, Inc. (OBIO), it’s important to track earnings outlook and estimate revisions for potential stock performance. Zacks Investment Research offers insights and tools for investors to make informed decisions. The Zacks Rank system has a strong track record of leveraging earnings estimate revisions for stock performance.



Read more at Nasdaq: Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates